Preclinical studies using established ovarian cancer cell lines have described combinations of PI3K inhibitors with chemotherapy17 and various agents targeting the RAS/ERK pathway18, EGFR19, mTOR20, and BCL-2-family proteins21, 22. The gene discussed is BCL2; the disease is ovarian cancer.